The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai; Seagen
Speakers' Bureau - Bayer
Research Funding - Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Guardant Health (Inst); HiberCell (Inst); Merck Serono (Inst); Roche/Genentech (Inst)
 
Katherine A Guthrie
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Benjamin R. Tan
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst); TYME (Inst)
 
Crystal S. Denlinger
Consulting or Advisory Role - BeiGene; Bristol Myers Squibb; Exelixis; Merck; Zymeworks
Research Funding - Agios (Inst); Amgen (Inst); Array BioPharma (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genmab (Inst); Macrogenics (Inst); MedImmune (Inst); Sanofi (Inst); Zymeworks (Inst)
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Incyte; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); Verastem (Inst)
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Arvind Dasari
Consulting or Advisory Role - Crinetics Pharmaceuticals; Novartis; Personalis; Voluntis
Research Funding - Eisai; Guardant Health; Hutchison MediPharma; Merck
 
Larry R. Corum
No Relationships to Disclose
 
Lee G. Hicks
No Relationships to Disclose
 
Mital Patel
No Relationships to Disclose
 
Benjamin T Esparaz
No Relationships to Disclose
 
Syed Mohammad Ali Kazmi
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Nitya Alluri
No Relationships to Disclose
 
Sarah Colby
No Relationships to Disclose
 
Sepideh Gholami
Consulting or Advisory Role - QED Therapeutics
Speakers' Bureau - Helsinn Therapeutics
 
Philip Jordan Gold
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - Axiom Healthcare Strategies; Bayer; BioNTech; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; Ipsen; Merck; Novartis; Noxxon Pharma; Noxxon Pharma; Pfizer; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); FibroGen (Inst); Halozyme (Inst); Lonza (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Stemline Therapeutics (Inst)
 
Howard S. Hochster
Stock and Other Ownership Interests - Compass Therapeutics; Processa Pharmaceuticals
Consulting or Advisory Role - Bayer; Genentech; Merck
Speakers' Bureau - Natera
 
Philip Agop Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals